| HOME >> BIOLOGY >> TECHNOLOGY |
QUEBEC CITY, Aug. 31 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG), a clinical-stage biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it was included in a report of President Obama's Council of Advisors on Science and Technology entitled "Report to the President on Reengineering the Influenza Vaccine Production Enterprise to Meet the Challenges of Pandemic Influenza", which was released earlier this month. U.S. Health and Human Services Secretary Kathleen Sebelius and other public health officials held a briefing to discuss this report and the $2 billion plan to accelerate the development of drugs and vaccines to prevent the spread of infectious diseases.
The report examined the importance to the U.S.A. of more rapidly and reliably producing effective vaccines, at a sufficient scale to protect all U.S. residents, in response to the emergence of pandemic influenza. The report stated, "Protecting the nation from an influenza pandemic...requires tightening the schedule for making vaccine substantially: in a serious pandemic, saving weeks could translate into saving tens of thousands of lives." Medicago was notably mentioned as an example of a recombinant influenza vaccine technology in clinical development.
"We are thrilled to be identified by the President's top scientific advisors as advancing the development of a recombinant vaccine technology that offers speed and cost advantages over the current method," said Andy Sheldon, President and CEO of Medicago.
The U.S. government's new initiative supports the development, clinical testing, and approval of influenza vaccines made using recombinant DNA technology. The investment strategy allows for flexibility in financing of promising vaccine production platforms, and creates downstream incentives for products that meet the target product profile and producti
'/>"/>
| SOURCE Medicago Inc. Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. Medicago reports positive Phase I results for its avian flu pandemic vaccine
2. Medicago to present at the U.S. Department of Health and Human Services Global Health Security Initiative Workshop
3. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
4. Medicago begins human clinical testing with its avian flu pandemic vaccine
5. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
6. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
7. Medicago succesfully expresses VLP antigen for A H1N1 strain
8. Medicago initiates work on Swine Flu strain
9. maxIT Healthcare Named to Inc. 5000 List
10. BioPharm Systems Named to the 2010 Inc. 500
11. 5000 List of Fastest-Growing Companies in the U.S.
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |